Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Recurrent Clostridioides difficile infection (rCDI) is linked to a reduction in microbial diversity and a decrease in microbe-derived secondary bile acids, which play a role in inhibiting the germination and growth of C. difficile. SER-109, an investigational microbiome drug composed of donor-derived, purified spores, demonstrated a reduction in recurrence during a dose-ranging, phase 1 study involving subjects with multiple rCDIs (1).
It is a double-blind…